Patrick Enright

Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA

Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA.

DiObex, Inc. develops therapies for metabolic disease treatment. Its products address the markets for the treatment of diabetes and its co-morbidities such as hypertension, dyslipidemia, and visceral adiposity. The company was founded in 2003 and is headquartered in San Francisco, CA.

Tecan Genomics, Inc. provides genomics sample preparation solutions. It offers solutions which make biological samples accessible for genomic analysis. The firm has commercialized numerous proprietary DNA and RNA sample preparation products for use in research and diagnostic applications. The company was founded by Jan D'Alvise, James W. Larrick and Nurith Kurn in 2000 and is headquartered in San Carlos, CA.

Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ.

MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA.

CardioDx, Inc. operates as a cardiovascular genomic diagnostics firm. It develops proprietary tests that improve treatment decisions and patient outcomes on coronary artery disease, cardiac arrhythmia, and heart failure. The company was founded by David L. Levison and Christopher R. Burrow in 2004 and is headquartered in Redwood, CA.

Raven Biotechnologies, Inc. engages in the development of antibody therapeutics for the treatment for cancer, autoimmune disorders and infectious diseases. Its products are used in treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 and is headquartered in South San Francisco, CA.

Prestwick Pharmaceuticals, Inc. develops drugs for diseases related to the central nervous system. Its drugs are used in curing diseases such as Huntington's, Parkinson's, restless legs syndrome, schizophrenia, autism, Alzheimer's, and sleep apnea diseases. The company was founded in 2002 and is headquartered in Washington DC.

InfaCare Pharmaceutical Corp. develops and commercializes proprietary pharmaceuticals for the neonatal and pediatric patient population. It offers Stanate, a heme oxygenase inhibitor for the treatment of infantile jaundice or hyperbilirubinemia. The company was founded by Robert A. Vukovich on July 5, 2005 and is headquartered in Trevose, PA.

Epirium Bio, Inc. develops therapeutics for orphan and rare diseases characterized by impairment of the skeletal muscle, cardiac and neuronal systems. The company was founded in 2008 by Alan Stewart Maisel, Sundeep Dugar, and Francisco Villarreal and is headquartered in Los Altos Hills, CA.

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

FirstMark Capital LLC (FirstMark Capital) is venture capital firm founded by Rick Heitzmann and Amish Jani in 1996. The firm is headquartered in New York.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare. It markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins. The firm's product candidates include XP12B, a tranexamic acid modified release oral tablet for the reduction of menstrual blood loss in women, who suffer from menorrhagia or excessive menstrual bleeding; and XP20B is a combination propoxyphene and acetaminophen modified release oral tablet for the treatment of mild to moderate pain. The company was founded by Gilbert R. Gonzales and Roger Dale Griggs in May 2001 and is headquartered in Newport, KY.

National Venture Capital Association provides business association services. It facilitates networking opportunities and provides research data to its members. The company is headquartered in Washington, DC.

Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.

Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ.

Longitude Capital Management Co LLC (Longitude Capital) is a venture capital firm founded in 2006 by Juliet Trammenoms Bakker, Patrick Enright, David Hirsch and Marc-Henri Galletti. The firm is headquartered in Menlo Park, California.

Lemo USA, Inc. designs and manufactures custom connectors. It offers low voltage connectors, plastic and miniature connectors, high pressure and high voltage connectors, media converter, and cable assemblies. The company is headquartered in Rohnert Park, CA.

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

Orbus Therapeutics, Inc. operates as a biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases. Its product eflornithine is a novel cytostatic agent, which the firm is developing to treat patients with recurrent anaplastic astrocytoma, a rare form of central nervous system cancer. The company was founded by Robert M. Myers and Jason D. Levin in 1998 and is headquartered in Palo Alto, CA.

CuraSen Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapies to treat neurodegenerative diseases, including parkinson, alzheimer, and less common neurodegenerative disorders. The company was founded by Mehrdad Shamloo, Robert Booth, Anthony Ford, and Kathleen Sereda in 2018 and is headquartered in San Mateo, CA.

Rivus Pharmaceuticals, Inc. is a company dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). The company is based in Charlottesville, VA. Jayson Donald Alexander Dallas has been the CEO of the company since 2021. The company is a leader in mitochondrial biology and is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity. Rivus' lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes.

Dascena, Inc. develops machine learning algorithms to enable early disease intervention. The company was founded by Ritankar Das and is headquartered in Oakland, CA.

Pequot Capital Corp. provides investment advisory services.

Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation.

Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland.